RT Journal Article
SR Electronic
T1 The Role of Age and Sex in Non-linear Dilution Adjustment of Spot Urine Arsenic
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.12.23288341
DO 10.1101/2023.04.12.23288341
A1 Carmine, Thomas Clemens
YR 2024
UL http://medrxiv.org/content/early/2024/06/30/2023.04.12.23288341.abstract
AB Background Previous research introduced V-PFCRC as an effective spot urinary dilution adjustment method for various metal analytes, including the major environmental toxin arsenic. V-PFCRC normalizes analytes to 1 g/L creatinine (CRN) by adopting more advanced power-functional corrective equations accounting for variation in exposure level. This study expands on previous work by examining the impacts of age and sex on corrective functions.Methods Literature review of the effects of sex and age on urinary dilution and the excretion of CRN and arsenic. Data analysis included a Data Set 1 of 5,752 urine samples and a partly overlapping Data Set 2 of 1,154 combined EDTA blood and urine samples. Both sets were classified into age bands, and the means, medians, and interquartile ranges for CRN and TWuAs in uncorrected (UC), conventionally CRN-corrected (CCRC), simple power-functional (S-PFCRC), sex-aggregated (V-PFCRC SA), and sex-differentiated V-PFCRC SD modes were compared. Correlation analyses assessed residual relationships between CRN, TWuAs, and age. V-PFCRC functions were compared across three numerically similar age groups and both sexes. The efficacy of systemic dilution adjustment error compensation was evaluated through power-functional regression analysis of residual CRN and the association between arsenic in blood and all tested urinary result modes.Results Significant sex differences in UC and blood were neutralized by CCRC and reduced by V-PFCRC. Age showed a positive association with blood arsenic and TWuAs in all result modes, indicating factual increments in exposure. Sex-differentiated V-PFCRC best matched the sex-age kinetics of blood arsenic. V-PFCRC formulas varied by sex and age and appeared to reflect urinary osmolality sex-age-kinetics reported in previous research.V-PFCRC minimized residual biases of CRN on TWuAs across all age groups and sexes, demonstrating improved standardization efficacy compared to UC and CCRC arsenic.Interpretation Sex differences in UC and CCRC arsenic are primarily attributable to urinary dilution and are effectively compensated by V-PFCRC. While the sex and age influence on V-PFCRC formulas align with sex- and age-specific urinary osmolality and assumed baseline vasopressor activities, their impact on correction validity for entire collectives is minimal.Conclusion The V-PFCRC method offers a robust correction for urinary arsenic dilution, significantly reducing systemic dilution adjustment errors. Its application in various demographic contexts enhances the accuracy of urinary biomarker assessments, benefiting clinical and epidemiological research. V-PFCRC effectively compensates for sex differences in urinary arsenic. Age-related increases in TWuAs are exposure-related and should be additionally accounted for by algebraic normalization, covariate models, or standard range adjustments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethic Committee of Northwest- and Central Switzerland (EKNZ), Hebelstrasse 53 4056 Basel. Tel. 061 268 13 50. Fax 061 268 13 51. Email: eknz@bs.chI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsATIIAngiotensin IIAVPArginine vasopressin (= Adiuretin, ADH)CCRCConventional Creatinine CorrectionCKDChronic Kidney DiseaseCRNCreatinineDMADimethylarsinic acidEEstrogenFGF23Fibroblast Growth Factor 23GCHPGlomerular Capillary Hydrostatic PressureGFRGlomerular Filtration RateiAsInorganic Arsenic (iAsIII + iAsV)%iAsPercentage of iAs in Total weight arseniciAsIIITrivalent ArseniteiAsVPentavalent ArsenateICP-MSInductively Coupled Plasma Mass SpectrometryMATE1Multidrug and Toxin Extrusion Protein 1m-KLProteohormone transmembrane KlothoMMAMonomethylarsonic acidNaPi-IIaSodium-coupled PO4− Co-TransportersNT-proBNPN-terminal pro B-type Natriuretic PeptideoAsOrganic Arsenic (Sum of DMA + MMA, Arsenobetaine, Arseno–sugars, –lipids, and –choline)OCT2Organic Cation Transporter 2uOsmUrinary OsmolalityPProgesteronePO4−PhosphateRAASRenin-Angiotensin-Aldosterone SystemRPFRenal Plasma FlowSAMeS-Adenosyl-MethionineS-PFCRCSimple Power Functional Creatinine Correction using fixed exponentsTTestosteroneTuAsSum of iAs and methylated primary metabolites of iAs (iAs + DMA + MMA)TWuAsTotal Weight Urinary Arsenic = all ICP-MS detectable forms of inorganic and organic arsenic (measured in this study)AsUCUncorrected TWuAs in µg/LuAsCConventionally Creatinine-corrected TWuAsuAsNUrinary Total Weight Arsenic, normalized to 1 g/L CRN by V-PFCRC SDUCUncorrected urinary result mode (in µg/L for Arsenic)uOsmUrinary OsmolalityV-PFCRCVariable Power Functional Creatinine Correction (all forms)V-PFCRC SASex-Aggregated Variable Power Functional Creatinine Correction using identical analyte-specific coefficients c and d for both sexesV-PFCRC SDSex-Differentiated Variable Power Functional Creatinine Correction using sex-specific coefficients c and d